Who gets chemotherapy for metastatic lung cancer?

Chest

Volumn 117, Issue 5, 2000, Pages 1239-1246

  Earle, Craig C ^a   Venditti, Laura N ^a   Neumann, Peter J ^b   Gelber, Richard D ^a   Weinstein, Milton C ^b   Potosky, Arnold L ^c   Weeks, Jane C ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD CENTER FOR RISK ANALYSIS   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Chemotherapy; Non small cell lung cancer; Practice patterns

Indexed keywords

ANTINEOPLASTIC AGENT;

AGED; ARTICLE; COST BENEFIT ANALYSIS; FEMALE; HEALTH INSURANCE; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDICARE; PREDICTION; PREVALENCE; PRIORITY JOURNAL; SCORING SYSTEM;

EID: 0034085866     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.117.5.1239     Document Type: Article

References (61)

1. 1 Reis LAG, Kosary CL, Hankey BF, et al. SEER cancer statistics review, 1973-1996. Bethesda, MD: National Cancer Institute, 1999
2. 2 Ihde DC. Chemotherapy of Lung Cancer. N Engl J Med 1992; 327:1434-1441
3. 3 DeVita VT Jr, Hellman S, Rosenberg SA. Cancer: principles and practice of oncology. Philadelphia, PA: J.B. Lippincott, 1993
4. 4 Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995; 311:899-909
5. 5 Ruckdeschel JC. Is chemotherapy for metastatic nonsmall-cell lung cancer "worth it" [editorial]? J Clin Oncol 1990; 8:1293-1296
6. 6 Tannock IF, Boyer M. When is cancer treatment worthwhile [editorial]? N Engl J Med 1990; 323:989-990
7. 7 American Society of Clinical Oncology. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. J Clin Oncol 1997; 15:2996-3018
8. 8 Lopez PG, Stewart DJ, Newman TE, et al. Chemotherapy in stage IV (metastatic) non-small-cell lung cancer. Cancer Prev Control 1997; 1:18-27
9. 9 Ettinger DS, Cox JD, Ginsberg RJ, et al. NCCN non-small-cell lung cancer practice guidelines. Oncology 1996; 10(Suppl):81-111
10. 10 Smith TJ, Penberthy LT, Desch CE, et al. Differences in initial treatment patterns and outcomes of lung cancer in the elderly. Lung Cancer 1995; 13:235-252
11. 11 Greenberg ER, Chute CG, Stukel T, et al. Social and economic factors in the choice of lung cancer treatment: a population-based study in two rural states. N Engl J Med 1988; 318:612-617
12. 12 Zippin C, Lum D, Hankey BF. Completeness of hospital cancer case reporting from the SEER program of the National Cancer Institute. Cancer 1995; 76:2343-2350
13. 13 Ries LAG, Kosary CL, Hankey BF, et al. SEER cancer statistics review, 1973-1994. Bethesda, MD: National Cancer Institute, 1997. NIH publication 97-2789.
14. 14 Nattinger AB, McAuliffe TL, Schapira MM. Generalizability of the surveillance, epidemiology, and end results registry population: factors relevant to epidemiologic and health care research. J Clin Epidemiol 1997; 50:939-945
15. 15 Potosky AL, Riley GF, Lubitz JD, et al. Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care 1993; 31:732-748
16. 16 Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1986; 40:373-383
17. 17 Charlson ME, Sax FL, MacKenzie CR, et al. Morbidity during hospitalization: can we predict it? J Chronic Dis 1986; 40:705-712
18. 18 Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. Clin Epidemiol 1992; 45:613-619
19. 19 Klabunde C. Assessment of comorbidity using claims data: SEER Medicare Data Users Workshop. Bethesda, MD: National Cancer Institute Applied Research Program, 1998
20. 20 Krieger N. Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology. Am J Pub Health 1992; 92:703-710
21. 21 Greenberg ER, Dain B, Freeman D, et al. Referral of lung cancer patients to university hospital cancer centers: a population-based study in two rural states. Cancer 1988; 62:1647-1652
22. 22 Hillner BE, McDonald MK, Desch CE, et al. A comparison of patterns of care of nonsmall cell lung carcinoma patients in a younger and Medigap commercially insured cohort. Cancer 1998; 83:1930-1937
23. 23 Kesson E, Bucknall CE, McAlpine LG, et al. Lung cancer management and outcome in Glasgow, 1991-92. Br J Cancer 1998; 78:1391-1395
24. 24 Raby B, Pater J, Mackillop W. Does knowledge guide practice? Another look at the management of non-small-cell lung cancer J Clin Oncol 1995; 13:1904-1911
25. 25 Crook A, Duffy A, Girling DJ, et al. Survey on the treatment of non-small cell lung cancer (NSCLC) in England and Wales. Eur Respir J 1997; 10:1552-1558
26. 26 Rapp E, Pater JL, Willan A, et al. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer: report of a Canadian multicenter randomized trial. J Clin Oncol 1988; 6:633-641
27. 27 Quoix E, Dietemann A, Charbonneau J, et al. La chimiotherapie comportant du cisplatin est-elle utile dans le cancer bronchique non microcellulaire au stade IV? Resultats d'une etude randomisee. Bull Cancer 1991; 78:341-346
28. 28 Cellerino R, Tummarello D, Guidi F, et al. A randomized trial of alternating chemotherapy versus best supportive care in advanced non-small cell lung cancer. J Clin Oncol 1991; 9:1453-1461
29. 29 The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 1999; 91:66-72
30. 30 Hynes DM. The quality of breast cancer care in local communities: implications for health care reform. Med Care 1994; 32:328-340
31. 31 Fireman BH, Quesenberry CP, Somkin CP, et al. Cost of care for cancer in a Health Maintenance Organization. Health Care Financ Rev 1997; 18:51-76
32. 32 Ayanian JZ, Guadagnoli E. Variations in breast cancer treatment by patient and provider characteristics. Breast Cancer Res Treat 1996; 40:65-74
33. 33 Desch CE, Penberthy LT, Newschaffer CJ, et al. Factors that determine the treatment for local and regional prostate cancer. Med Care 1996; 34:152-162
34. 34 Bennett CL, Greenfield S, Aronow H, et al. Patterns of care related to age of men with prostate cancer. Cancer 1991; 67:2633-2641
35. 35 Hillner BE, Penberthy LT, Desch CE, et al. Variation in staging and treatment of local and regional breast cancer in the elderly. Breast Cancer Res Treat 1996; 40:75-86
36. 36 Goel V, Olivotto IA, Hislop TG, et al. Patterns of initial management of node-negative breast cancer in two Canadian provinces. Can Med Assoc J 1997; 156:25-35
37. 37 Ruckdeschel JC, Finkelstein DM, Ettinger DS, et al. A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer. J Clin Oncol 1986; 4:14-22
38. 38 Extermann M, Overcash J, Lyman GH, et al. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 1998; 16:1582-1587
39. 39 Ballard-Barbash R, Potosky AL, Harlan LC, et al. Factors associated with surgical and radiation therapy for early stage breast cancer in older women. J Natl Cancer Inst 1996; 88:716-726
40. 40 Schulman KA, Berlin JA, Harless W, et al. The effect of race and sex on physicians' recommendations for cardiac catheterization. N Engl J Med 1999; 340:618-626
41. 41 Ayanian JZ, Epstein AM. Differences in the use of procedures between women and men hospitalized for coronary heart disease. N Engl J Med 1991; 325:221-225
42. 42 Ganz PA. Age and gender as factors in cancer therapy. Clin Geriatr Med 1993; 9:145-155
43. 43 Michalski TA, Nattinger AB. The influence of black race and socioeconomic status on the use of breast-conserving surgery for Medicare beneficiaries. Cancer 1997; 79:314-319
44. 44 Ayanian JZ, Udvarhelyi IS, Gatsonis CA, et al. Racial differences in the use of revascularization procedures after coronary angiography. JAMA 1993; 269:2642-2646
45. 45 Ball JK, Elixhauser A. Treatment differences between blacks and whites with colorectal cancer. Med Care 1996; 34:970-984
46. 46 Burns RB, McCarthy EP, Freund KM, et al. Black women receive less mammography even with similar use of primary care. Ann Intern Med 1996; 125:173-182
47. 47 Klabunde CN, Potosky AL, Harlan LC, et al. Trends and black/white differences in treatment for nonmetastatic prostate cancer. Med Care 1998; 36:1337-1348
48. 48 Hislop TG, Olivotto IA, Goldman AJ, et al. Variations in breast conservation surgery for women with axillary lymph node negative breast cancer in British Columbia. Can J Public Health 1996; 87:390-394
49. 49 Lantz PM, House JS, Lepkowski JM, et al. Socioeconomic factors, health behaviors, and mortality. JAMA 1998; 279: 1703-1708
50. 50 Lipworth L, Lee JAH, Morris JN. Case-fatality in teaching and non-teaching hospitals, 1956-1959. Med Care 1963; 1:71-76
51. 51 Farrow DC, Hunt WC, Samet JM. Geographic variation in the treatment of localized breast cancer. N Engl J Med 1992; 326:1097-1101
52. 52 Guadagnoli E, Hauptman PJ, Ayanian JZ, et al. Variation in the use of cardiac procedures after acute myocardial infarction. N Engl J Med 1995; 333:573-578
53. 53 Guadagnoli E, Ayanian JZ, Gibbons G, et al. The influence of race on the use of surgical procedures for treatment of peripheral vascular disease of the lower extremities. Arch Surg 1995; 130:381-386
54. 54 Lu-Yao GL, Greenberg ER. Changes in prostate cancer incidence and treatment in USA. Lancet 1994; 343:251-254
55. 55 Weeks J, Pfister DG. Outcomes research studies. Oncology 1996; 10(11 Suppl):29-34
56. 56 Epstein AM, Stern RS, Tognetti J, et al. The association of patients' socioeconomic characteristics with the length of hospital stay and hospital charges within diagnosis-related groups. N Engl J Med 1988; 318:1579-1585
57. 57 Dayal HH, Polissar L, Dahlbert S. Race, socioeconomic status, and other prognostic factors for survival from prostate cancer. J Natl Cancer Inst 1985; 74:1001-1006
58. 58 Whittle J, Steinberg EP, Anderson GF, et al. Accuracy of Medicare claims data for estimation of cancer incidence and resection rates among elderly Americans. Med Care 1991; 29:1226-1236
59. 59 Riley GF, Potosky AL, Klabunde CN, et al. Stage at diagnosis and treatment patterns among older women with breast cancer: an HMO and fee-for-service comparison. JAMA 1999; 281:720-726
60. 60 Frey CM, McMillen MM, Cowan CD, et al. Representativeness of the Surveillance, Epidemiology, and End Results program data: recent trends in cancer mortality rates. J Natl Cancer Inst 1992; 84:872-877
61. 61 Riley GF, Potosky AL, Lubitz JD, et al. Stage of cancer at diagnosis for Medicare HMO and fee-for-service enrollees. Am J Public Health 1994; 84:1598-1604